Amphetamines in child medicine: a review of ClinicalTrials.gov
Frontiers in Pharmacology · 03.10.2023 · 14
DOI: 10.3389/fphar.2023.1280562 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 03.10.2023. Verfasst von Samer O Alalalmeh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center of Medical and Bio-Allied Health Sciences Research, Ajman University, Ajman, United Arab Emirates. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Globally, the use of amphetamines as therapeutic agents in pediatric medicine is a crucial area of concern, especially given the population’s vulnerability.
Methods
On 6 August 2023, a search was conducted on ClinicalTrials.gov using “amphetamine” as the keyword. Two independent examiners screened trials against set criteria, including a focus on amphetamine, completion status, an interventional approach, and included children. Ongoing or observational studies were excluded. Data extracted from the qualified trials encompassed primary objectives, participant counts, study duration, and outcomes, with the aim of analyzing children disorders treated by amphetamine.
Results
On 6 August 2023, a search of the ClinicalTrials.gov database with the term “amphetamines” identified 179 clinical trials. After extensive exclusion criteria, 19 trials were ultimately selected for analysis. The predominant condition under investigation was attention deficit hyperactivity disorder (ADHD), present in 84.2% of studies. Key study characteristics included: phase 4 trials (36.8%), randomized allocation (63.2%), and the parallel intervention model (42.1%). Masking techniques varied, with no masking in 42.1% of studies, and double and quadruple masking both accounting for 21.1%. Geographically, 78.9% of the studies’ participants were from the United States.
Conclusion
This study highlights the notable therapeutic potential of amphetamines in pediatric ADHD populations and emphasizes the importance of recognizing potential side effects and addiction risks. As pharmacogenomics offers the prospect of personalized treatments, there is potential to increase therapeutic efficacy and decrease adverse reactions. It is vital to balance these benefits against the inherent risks, understanding the need for continued research to optimize the use of amphetamines in medicine.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center of Medical and Bio-Allied Health Sciences Research, Ajman University, Ajman, United Arab Emirates.
- Department of Clinical Sciences, College of Pharmacy and Health Sciences, Ajman University, Ajman, United Arab Emirates.
- Department of Pharmacology and Toxicology, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
Zitieren
APA
Alalalmeh, S. O., Hegazi, O. E., Shahwan, M., Alshehri, F. S., Ashour, A. M., Algarni, A. S., & Alorfi, N. M. (2023). Amphetamines in child medicine: a review of ClinicalTrials.gov. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1280562
Vancouver
Alalalmeh SO, Hegazi OE, Shahwan M, Alshehri FS, Ashour AM, Algarni AS, et al. Amphetamines in child medicine: a review of ClinicalTrials.gov. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1280562
BibTeX
@article{Alalalmeh2023,
author = {Alalalmeh, Samer O and Hegazi, Omar E and Shahwan, Moyad and Alshehri, Fahad S and Ashour, Ahmed M and Algarni, Alanood S and Alorfi, Nasser M},
title = {Amphetamines in child medicine: a review of ClinicalTrials.gov},
journal = {Frontiers in Pharmacology},
year = {2023},
volume = {14},
doi = {10.3389/fphar.2023.1280562}
}
EUVIMED